Menu
Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 51-60 of 64
Pediatric Blood Cancer
A Phase I/II of Nivolumab in Combination with Chemotherapy in pediatric patients with relapsed/refractory acute myeloid leukemia
A Phase I/II of Nivolumab in Combination with Chemotherapy in pediatric patients with relapsed/refractory acute myeloid leukemia Summary: Despite advances in treatment of AML, the long-term survival rate of children with relapsed AML has not changed significantly and remains poor. Intensification of conventional chemotherapy leads to increases in drug toxicity without improvement in outcomes. Therefore, […]
Anupam Verma, MD
University of Utah
Pediatric Blood Cancer
The safety and tolerability of intravenous fish oil lipid emulsion in children undergoing hematopoietic cell transplantation
The safety and tolerability of intravenous fish oil lipid emulsion in children undergoing hematopoietic cell transplantation Summary: Hematopoietic Stem cell transplant (HSCT) is a potentially life-saving treatment for many patients with blood cancers and is generally the preferred approach for children with a high risk of relapsed disease. However, HSCT is associated with significant toxicity […]
Alexandra Carey, MD
Boston Children's Hospital
Solid Tumors
Fecal microbiota transplantation (FMT) treatment for immune checkpoint inhibitor–mediated colitis
Fecal microbiota transplantation (FMT) treatment for immune checkpoint inhibitor–mediated colitis Summary: Immune checkpoint inhibitors (ICIs) have become paradigm-shifting therapies for a variety of cancers. However, these agents are associated with various toxicities that affect the skin, GI tract, liver, lungs, endocrine system, and nervous system. Immune-mediated colitis (IMC) is among the most encountered severe toxicities […]
Yinghong Wang, MD, PhD
MD Anderson Cancer Center
Breast Cancer
Identification of Predictive Protein Pathway Activation Biomarkers for Neoadjuvant Breast Cancer Therapy Treatment from the ISPY2 TRIAL
Identification of Predictive Protein Pathway Activation Biomarkers for Neoadjuvant Breast Cancer Therapy Treatment from the ISPY2 TRIAL Summary: Over 200,000 women are diagnosed with breast cancer annually in the United States and breast cancer is responsible for approximately 45,000 deaths annually in the U.S. While those diagnosed with early-stage breast cancer have excellent outcomes, 10-20% […]
Emanuel Petricoin, PhD
George Mason University
Breast Cancer
Copper depletion as a therapeutic strategy to prevent metastases in triple negative breast cancer: Unraveling the mechanisms behind the effect of copper depletion on the tumor and tumor microenvironment
Copper depletion as a therapeutic strategy to prevent metastases in triple negative breast cancer: Unraveling the mechanisms behind the effect of copper depletion on the tumor and tumor microenvironment Summary: Triple-negative breast cancer (TNBC) is an aggressive cancer that accounts for 15-20% of all breast cancer cases; however, it is responsible for 50% of metastasis-related […]
Linda Vahdat, MD, MBA
Dartmouth
Breast Cancer
Immune Effects of Sacituzumab Govitecan with or without Pembrolizumab in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer
Immune Effects of Sacituzumab Govitecan with or without Pembrolizumab in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer Summary: Worldwide, breast cancer is the most common non-skin cancer and the leading cause of cancer death in women. In the United States, breast cancer accounts for nearly one-third of all new cancer diagnoses among women with over 250,000 […]
Sara Tolaney, MD, MPH
Dana-Farber Cancer Institute
Pediatric Sarcoma
Phase 2 Study of Regorafenib in Combination with Immune Checkpoint Inhibitor Nivolumab in Patients with Refractory or Recurrent Osteosarcoma
Phase 2 Study of Regorafenib in Combination with Immune Checkpoint Inhibitor Nivolumab in Patients with Refractory or Recurrent Osteosarcoma Summary: Osteosarcoma is the most common malignant bone tumor in children and young adults, with a peak incidence between 13 and 16 years of age. The mainstay of treatment is intensive multi-agent cytotoxic chemotherapy but despite […]
Fariba Navid, MD
Children's Hospital Los Angeles
Pancreatic Cancer
A Phase 1b/2 Trial of Immunotherapy with Avelumab and Pepinemab as Second Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma
A Phase 1b/2 Trial of Immunotherapy with Avelumab and Pepinemab as Second Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma Summary: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers and an almost uniformly fatal malignancy. Treatment outcomes remain dismal with a 5-year survival of 9%. The incidence of PDAC is increasing and […]
David Linehan, MD
University of Rochester
Pediatric Rare Cancer
Phase 2 study of nivolumab and ipilimumab in children and young adults with relapsed or refractory INI1-negative cancers
Phase 2 study of nivolumab and ipilimumab in children and young adults with relapsed or refractory INI1-negative cancers Summary: INI1 is a tumor suppressor gene and several aggressive pediatric tumor types are characterized by INI1 negativity, including rhabdoid tumors, epithelioid sarcoma, and chordoma. These cancers represent a portion of rare tumor diagnoses and each are […]
Suzanne Forrest, MD
Dana-Farber Cancer Institute
Head/Neck Cancer
Harnessing Innate Immunity in Solid Tumors: CTLA-4 Inhibition in Combination with Memory-like Natural Killer (NK) Cell Immune Cell Therapy in Advanced Head & Neck Cancer
Harnessing Innate Immunity in Solid Tumors: CTLA-4 Inhibition in Combination with Memory-like Natural Killer (NK) Cell Immune Cell Therapy in Advanced Head & Neck Cancer Summary: Outcomes for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) remain quite poor with survival measured in months in most cases. Immunotherapy, specifically […]
Rizwan Romee, MD
Dana-Farber Cancer Institute
